Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
BetterLife Pharma ( (TSE:BETR) ) just unveiled an announcement.
BetterLife Pharma announced that the USPTO granted a composition of matter patent for BETR-001, a non-hallucinogenic LSD derivative with significant commercial potential. This patent strengthens BetterLife’s intellectual property position, ensuring protection and viability for BETR-001 in treating various mental health disorders.
More about BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing compounds to treat neuro-psychiatric and neurological disorders. Its primary compounds include BETR-001, a non-hallucinogenic LSD derivative, and BETR-002, based on honokiol, aimed at treating anxiety-related disorders.
YTD Price Performance: 8.00%
Average Trading Volume: 27,186
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $10.36M
Learn more about BETR stock on TipRanks’ Stock Analysis page.
